# Nasdaq

Type: Company (NDAQ)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/nasdaq
Canonical HTML page: https://getbiobrief.com/entity/nasdaq

## Timeline

- **2026-Q4**: Potential Extension — Aptorum may apply for a second 180-day period if compliance is not met but criteria are satisfied.
- **2026-09-02**: Initial Compliance Deadline — End of the first 180-day grace period to regain a $1.00 closing bid price.
- **2026-07-27**: Completion of Parallel Asset Acquisition — SNDL completed the transaction, obtaining indirect majority economic exposure to Parallel’s operations via Sunstream and TransactionCo.
- **2026-04-29**: Announcement of Parallel Transaction — SNDL publicly announced the planned acquisition of assets of Surterra Holdings (Parallel) through a strict foreclosure agreement.
- **2026-03-19**: Q4 2025 Earnings Call — Management discussed clinical progress of Lomecel-B and financial outlook.
- **2026-03-12**: Capital Raise — Entry into a material definitive agreement for the sale of unregistered equity securities.
- **2026-03-09**: NASDAQ Compliance Notice — Longeveron received notice of failure to satisfy NASDAQ listing rules.
- **2026-03-06**: Deficiency Notice Received — Nasdaq notifies Aptorum of non-compliance with the $1.00 minimum bid price rule.

## Recent coverage (5 stories)

### SNDL Secures 69.4% Debt Control via Parallel Foreclosure, Prepares Pharma-Style Consolidation
2026-07-27 18:29:34 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

The acquisition of Parallel gives SNDL indirect control over vertically integrated medical cannabis operations, potentially accelerating drug development and GMP-compliant manufacturing paths ahead of an expected Nasdaq consolidation.
Full story: https://getbiobrief.com/story/sndl-parallel-biotech-cannabis-acquisition

### Longeveron Navigates Capital Constraints Amid Lomecel-B Clinical Progress
2026-03-19 13:50:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.
Full story: https://getbiobrief.com/story/longeveron-q4-2025-earnings-clinical-milestones-financial-headwinds

### Aptorum Faces Nasdaq Delisting Risk Amid Minimum Bid Price Deficiency
2026-03-06 22:24:58 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aptorum Group Limited (APM) has received a formal deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price required for continued listing. The company now enters a critical 180-day window to regain compliance, highlighting the ongoing financial pressures facing small-cap clinical-stage biotech firms.
Full story: https://getbiobrief.com/story/aptorum-nasdaq-minimum-bid-price-deficiency

### ImmunityBio Shares Surge as EU Approves ANKTIVA for Bladder Cancer
2026-02-18 23:26:51 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Full story: https://getbiobrief.com/story/immunitybio-anktiva-eu-approval-bladder-cancer

### Beta Bionics and NeoGenomics Signal Strong 2026 Outlook in Q4 Results
2026-02-18 21:00:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Beta Bionics and NeoGenomics reported robust Q4 2025 results, highlighting significant commercial momentum in autonomous insulin delivery and oncology diagnostics. Both companies emphasized operational efficiency and market expansion as key drivers for the upcoming fiscal year.
Full story: https://getbiobrief.com/story/beta-bionics-neogenomics-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.